EarlyCDT Lung for assessing risk of lung cancer in solid lung nodules

Following consideration of evidence identified during the scoping stage of the assessment on the use of EarlyCDT Lung in the clinical population that is defined in the scope, NICE believes that it will not be beneficial to develop an economic model to assess the cost effectiveness of the technology at this time. We are aware of the clinical interest in this area. We believe that identifying areas for further research and encouraging data collection would be useful to the system and could facilitate an assessment of the cost effectiveness in the future. The final guidance, will therefore focus on identifying areas for further research/ data collection, but will not make recommendations on cost effectiveness at this stage.